Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
TRACON Retains Global Rights to TRC253 Following Completion of a Phase 1/2 Trial
Details : The announcement came in the sense of Janssen Pharma's decision not to exercise their option to re-acquire TRC253's global rights after a analysis of the data in Phase 2.
Product Name : TRC253
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
April 24, 2020